Therapeutics Accelerator
Launching a New Era in Rare Disease Treatments
The Therapeutics Accelerator is a pioneering model to advance the development of innovative treatments for rare diseases. Via this, the Oxford-Harrington Rare Disease Centre (OHC) will identify, fund, and advance groundbreaking projects from academic partners in the UK, US and Canada into treatments for those living with rare diseases.
Powered by Collaboration
Our initiative is powered by a partnership between Harrington Discovery Institute at University Hospitals in Cleveland, the University of Oxford, and Oxford Science Enterprises (OSE). This collaboration is set to redefine the landscape of rare disease therapeutics.
Fostering Innovation
At the heart of the Accelerator is a commitment to innovation. We operate a unique non-profit/for-profit model, aiming to commit up to £200 million into new projects. Our funding is complemented by research, drug development, commercial strategy, and business development expertise. Our industry leaders bring a wealth of experience in bringing new drugs to market.
Case Study: Pioneering Investment in Rare Lung Disease
AlveoGene was launched in September 2023 to develop unique inhaled gene therapies for rare respiratory disorders. This new gene therapy company was created through the OHC Therapeutics Accelerator model, with investment from Oxford Science Enterprises, Harrington Discovery Institute, and Old College Capital. AlveoGene employs a proprietary lentiviral gene therapy platform for inhaled delivery of nucleic acid therapies.